# 1 Evaluating the Effectiveness of a Population-Level Health Intervention to Increment HCV

# 2 Treatment Coverage in Tuscany Region, Italy: An Interrupted Time Series Analysis.

3

## 4 Short title: HCV treatment coverage in Italy

- 5
- 6 Chiara Seghieri<sup>1</sup>, Luca Ceccarelli<sup>1-2\*</sup>, Costanza Tortù<sup>1</sup>, Lara Tavoschi<sup>2</sup>
- 7 1. Management and Healthcare Laboratory, Sant'Anna School of Advanced Studies, Pisa, Italy
- 8 2. Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa,
   9 Italy
- 10 \*corresponding author
- 11 Email: luca.ceccarelli15@studio.unibo.it
- 12

## 13 Abstract

14 Worldwide, an estimated 71.1 million people are chronically infected with the Hepatitis C virus (HCV). The

15 advent of direct-acting antivirals (DAAs) has made possible the definition of elimination targets by 2030. This

16 study aimed to evaluate the effectiveness of a population-level health intervention to expand access to HCV

17 treatment in the Tuscany Region, Italy.

18 We used individual-level administrative data from the Tuscany region, collected between January 2015 and 19 December 2022. Data include monthly observations on i) the number of serological tests to detect HCV, ii) the 20 number of PCR tests to detect HCV and, iii) the number of prescriptions of direct-acting antivirals against HCV.

21 We implemented an Interrupted Time Series (ITS) model, where the primary outcome was the number of

22 monthly prescriptions of direct-acting antivirals, while the number of tests to detect HCV were included as 23 control variables. The analysis was implemented i) in the general population, ii) in specific sub-population 24 groups.

Results show that the health intervention promoted by the Tuscany Regional Health Authority was highly effective in increasing DAAs treatment coverage in the general population, while no significant effects were observed among sub-population groups.

- Findings of this study provide evidence to support policies at national and subnational levels to booster HCVscreening and simplify access to DAA prescriptions.
- 30

31 Keywords: HCV; DAA treatment; interrupted time series; HCV screening; HCV diagnosis; health policy evaluation

1	2	

- 34

33

35 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 36 INTRODUCTION

37

38 Acute and chronic hepatitis can be brought on by the hepatitis C virus (HCV), which increases the risk 39 of cirrhosis, liver cancer, and death<sup>1-2</sup>. An estimated 3.9 million people in the European 40 Union/Economic European Area (EU/EEA) are among the 57.8 million people with HCV<sup>3</sup> who are 41 chronically infected worldwide. Due to the fact that chronic HCV infection is frequently asymptomatic, 42 a significant number of infected individuals go undiagnosed<sup>4</sup>. The prevalence of HCV is unequally 43 distributed throughout the population, with people living in prison (PLP), people who use drugs 44 (PWUD), people living withHIV-positive (PLHIV), or people with certain chronic illnesses (e.g. patients 45 undergoing hemodialysis, diabetics, or those who received blood or other products of human origin) 46 being disproportionately affected<sup>5</sup>. At present, no studies have evaluated the effectiveness of 47 population-level health policies implemented to increment HCV test and treatment coverages in Italy.

48 According to the available evidence<sup>6-11</sup>, an estimated 398,610 people in Italy (1.7% of the population) 49 have active HCV infection, with central regions having the highest prevalence (0.88%), followed by 50 southern and island regions (0.72% and 0.67%), and northern regions (0.54%)<sup>12-13</sup>. Existing surveillance 51 for viral hepatitis in Italy only monitors acute cases<sup>8</sup>, thus limiting the system's ability to assess the 52 burden of both acute asymptomatic and chronic illness. Large clinical cohort studies were established 53 to foster research initiatives, primarily on clinical grounds<sup>12</sup>. Epidemiological research using 54 administrative health information and data linkage approaches have been rarely used to overcome 55 the lack of data. A data-linkage study was carried out in Tuscany, a region with more than 3 million 56 inhabitants, to estimate the prevalence of people with chronic HCV infection and in need of treatment 57 by the end of 2015<sup>14</sup>. This and other seroprevalence studies conducted in Italy<sup>15</sup>, concur to an 58 estimated prevalence of 1%.

59 The HCV elimination targets by 2030, including a decrease in the percentage of undiagnosed cases 60 and an increase in treatment coverage, were made achievable by the development of direct-acting 61 antivirals (DAA). The World Health Organization (WHO) defined numerous targets along the 62 continuum of care for HCV to help reach this goal, including the diagnosis and treatment of 90% of 63 persons with chronic HCV infection by 2030<sup>16</sup>. The European Office of the WHO has developed a 64 Regional Action Plan that prioritizes efforts to combat disease and adapt global targets to the regional 65 epidemiological context<sup>17</sup>. The Italian National Plan for the Prevention of Viral Hepatitis (PNEV), 66 approved by the Italian Ministry of Health in 2015<sup>18</sup>, included the global and regional objectives for 67 HCV eradication.

68 Since 2014, patients with severe diseases in Italy have been entitled to receive free therapy at the 69 point of care upon a specialist's prescription. Through a monitoring registry for DAAs, the Italian 70 Medicines Agency (AIFA) keeps track of new patients who start receiving medication 71 (https://www.aifa.gov.it/aggiornamento-epatite-c). With the 2017 AIFA resolution, expanded access 72 to DAA has been achieved in Italy<sup>19</sup> and a national registry of patients initiating treatment was 73 established and updated regularly. At regional level, in Tuscany a triennial regional action plan was 74 launched in 2018 with the aim of raising the treatment coverage and contributing to the elimination 75 of HCV in the region<sup>20</sup>. The plan foresaw more than 6,000 HCV chronically infected individuals to be 76 treated every year up to 2020. Yet, identification of infected individuals and linkage to care posed a 77 challenge to the achievement of elimination targets. A national one-time screening program<sup>23</sup> was 78 launched at the end of 2021 with a focus on PLP, PWUD, and the birth cohorts from 1969 to 1989, 79 approximately corresponding to the people aged between 33 and 53.

Given these premises, the goal of this study is twofold: a) to evaluate the effectiveness of the population-level health interventions implemented since 2018 in Tuscany to expand access to HCV treatment b) to evaluate the impact of COVID-19 pandemic on the regional action plan. Interrupted time series analysis was applied on the monthly time series health administrative data to evaluate the effect of the regional plan. Study results provide valuable evidence for decision-makers including recommendations on further interventions that may be needed.

#### 87 MATERIAL AND METHODS

88

#### 89 Tuscany Regional Healthcare System

90 The National Health Service (NHS) is the national healthcare system in Italy. There are three tiers to 91 the system organization: local, regional, and national. The national level is in charge of defining the 92 overarching goals and core values of the NHS. The two Autonomous Provinces (R&AP) and the 19 93 regions are in charge of planning and executing the provision of healthcare. Local health authorities 94 (LHAs) in each region are responsible for providing primary care, public health services, community 95 health services, and specialized treatment either directly or through public hospitals or private 96 providers with accreditation. Each LHA's geographic area is further subdivided into Health Care 97 Districts (HCD), which are in charge of offering primary care and public health services.<sup>24</sup>.

98 The Italian health care system provides free care to every citizen who has a specific code for exemption 99 from healthcare costs (exemption code). Exemption codes may be given to individuals after the 100 diagnosis of a specific disease (e.g. HCV) or because of a particular socio-medical condition requiring 101 tailored care and treatments (e.g. problematic drug use, imprisonment).

102 Tuscany is a region of central Italy that counts 3,673,347 inhabitants with three LHA (North-West, 103 Center, South-East) and four university hospitals, to which 12 territories (provinces) refer. In Tuscany, 104 about 90% of healthcare services are delivered by entities that are either public providers or private 105 accredited providers. In the region there are 14 prisons, 40 harm reduction services (SerD) and 16 106 recognized non-governmental organizations (NGOs) that provide services to PWUD. The LHA (Ausl), 107 3 in Tuscany region, are territorial branches of the regional health service and guarantee the 108 homogeneity of assistance in the different areas of the region. Divided into district-areas, they provide 109 for the management and planning of the activities defined in the uniform and essential levels of care, 110 including socio-medical services with high health integration, health services of social relevance and 111 social assistance activities delegated to local authorities.

## 113 Sources of data

We used individual-level administrative data from the Tuscany region, collected between January 2015 and December 2022. The system can track each healthcare service, identified in the system by a unique code, provided to each individual, identified in the system by a unique personal identifier (alphanumeric code). However, outcomes of the services provided (e.g., exams' results) were not available in the system in line with current national and regional privacy regulations.

119 All data recorded in the Tuscan healthcare administrative databases are pseudo-anonymized at the 120 Regional Health Information System Office whereby each individual is assigned a unique identifier. 121 The study was carried out in compliance and accordance with the General Data Protection Regulation (2016/679) and the Italian Legislative Decree No. 196/2003 ("Personal Data Protection Code ") within 122 123 the project OPT-HepaC - Optimisation of diagnosis and treatment pathways for HCV in Tuscany – a 3-124 year project funded by Bando Ricerca Salute 2018 of Tuscany Region (Italy) for supporting the regional 125 bodies in the implementation of the HCV regional plan for 2018-2020 (DGR397/2018) (ethical approval 126 received by the Regional Ethics Committee of Tuscany Region).

127

We used four sources of data: (i) outpatient care data (SPA); (ii) drug prescription data (SPF and FES);
(iii) exemption codes data flow (RFC 192); and (iv) data about socio-demographic information on all
individuals enrolled in the Tuscan healthcare system, including sex, date of birth, and date of death.

131

#### 132 Data manipulation

We built a dataset that included monthly observations - collected between January 2015 and
December 2022 - on i) the number of serological tests to detect HCV (SPA) ii) the number of PCR tests
to detect HCV (SPA) and iii) the number of prescriptions of direct-acting antivirals (SPF and FES).

Individuals who had been linked to at least one step of the hepatitis C care pathway between 2015
and 2021 were included in the study. These were individuals who had received a screening or
diagnostic HCV test and/or a DAA prescription recorded in the health information system. Outpatient

139 services data were used to identify patients that had entered the HCV pathway via screening or 140 through diagnostic test at least once in the study period. Pharmaceutical services records gather data 141 about drug prescriptions which were used to identify patients treated with DAA. Each patient in the 142 dataset was identified through a unique code conferred by the regional agency for healthcare to 143 ensure pseudo-anonymization. This aggregation was implemented while considering i) the individuals 144 enrolled in the Tuscan healthcare system; ii) the sub-population of patients aged between 33 and 53 145 years old targeted by the national HCV screening; iii) sub-population at high risk for HCV infection, 146 namely PLP and PWUD. Data on both serological and PCR tests for the diagnosis of HCV were included 147 assuming serological test was performed for screening purposes while PCR for HCV-RNA identification 148 was performed for diagnosis confirmation purposes and for treatment follow up. Data on the number 149 of tests performed were sourced from SPA, however no test result was available. We used the 150 information on the confirmatory PCR test as a proxy to identify HCV-infected individuals. We defined 151 the primary outcome of interest as the ratio between the number of prescriptions for DAA and the 152 number of confirmatory PCR tests conducted in the preceding month. This ratio estimated the extent 153 of timely linkage to care and treatment for HCV-infected individuals recently diagnosed. The one-154 month period was defined based on available data: on average, patients who make the serological 155 test undergo a confirmatory PCR test within one month and receive a DAA prescription within the 156 following 4-week period.

157

## 158 Interrupted Time Series Approach

To assess the effect of the regional action plan implemented by Tuscany Regional Health Authority, we used a methodological framework based on *Interrupted Time Series*. Interrupted time series analysis<sup>25-26</sup> is a statistical methodology used to evaluate the impact of an intervention on a particular outcome over time. It is a very flexible framework employed to analyze empirical applications that refer to various fields of social sciences including public health<sup>27-28</sup>, economics<sup>29-30</sup>, political sciences<sup>31-</sup> <sup>32</sup>, and education<sup>33-34</sup>. The goal is to assess whether an intervention causes a significant change in the trend of a dependent variable (the outcome). In an interrupted time series design, data are collected at multiple time points both before and after the intervention. The intervention is introduced at a specific point in time, known as the *interruption*. The key idea is to compare the trajectory of the outcome variable before and after the intervention to estimate the actual effect of the intervention.

169

We obtained monthly observations of all the quantities of interest, observed between January 2015 and December 2022. The intervention of interest was the AIFA resolution promoted in April 2017, which was represented by a dummy variable that equals 1 in all the month-year observations occurring after April 2017, and 0 otherwise. The primary outcome of our study was given by the ratio between the number of prescriptions for direct-acting antivirals against HCV and the number of PCR tests conducted to detect HCV in the preceding month. This response variable has been normalized according to an *Ordered-Quantile (ORQ)* normalization transformation<sup>39</sup>.

177 We also included as control variables the number of serological tests to detect HCV performed two 178 months prior to the observation and a dummy variable which equals one in all the month-year 179 observations occurring after the identification of the first COVID cases (we considered March 2020 as 180 starting point of the COVID pandemic). Moreover, introducing lagged structure of the data allows to account for potential endogeneity. To also account for temporal autocorrelation, we chose to adopt 181 an ARIMA (AutoRegressive Integrated Moving Average)<sup>35-36</sup> model specification within the ITS design. 182 183 ARIMA models are particularly useful when the data shows a non-random, time-dependent 184 structure<sup>37</sup>. The ARIMA model is defined by three parameters (p, d, q): the parameter p is the order of 185 the AutoRegressive (AR) component, which represents the number of lagged observations used for 186 prediction; the parameter d is the degree of differencing (integration) required to make the time series 187 stationary. If d = 0, it means no differencing is needed; if d = 1, first-order differencing is applied, and 188 so on; q is the order of the Moving Average (MA) component, which represents the number of lagged 189 forecast errors used for prediction. The order of these components is usually determined through data 190 exploration and analysis: for instance, it can be chosen by examining the autocorrelation and partial

191 autocorrelation plots or by checking at the goodness of fit and the performance of various statistical 192 models, defined using alternative values of the parameters (p, d, q). In this work, we decided to follow 193 this second approach and, for each model, we decided the value of the parameters (p, d, q) by 194 comparing results obtained using different values of these parameters (the choice of the parameters 195 results from the implementation of the *auto.arima* function of the Forecast R package in R)<sup>38</sup>. 196 197 RESULTS 198 199 In this section, we mainly focus on the results obtained in the general cohort of people, in the general 200 cohort of people aged between 33 and 53 and in the cohort that include both PLP and PWUD; 201 however, all the other findings are available in the Supplementary Material - Appendix B.

202 In the observed time frame, Tuscany regional health authority delivered, 561874 serological tests, 203 79912 PCR tests and 13098 DAA prescriptions; people in the generic population received 561874 204 serological tests, 79912 PCR tests and 13098 DAA prescriptions; people aged between 33 and 53 205 received 242725 serological tests, 25370 PCR tests and 4695 DAA, while people with exemptions (PLP 206 and PWUD) received 15191 serological tests, 4361 PCR tests and 1210 DAA prescriptions. In the same 207 period, 163177 people aged between 33 and 53 received a serological test to detect early signs of 208 HCV, 10079 individuals received a screening through PCR test and 4339 were treated through DAA. 209 Figures A1, A2 and A3 in the Supplementary Material, Appendix A, illustrate the distribution of 210 prescribed DAA, the number of examined PCR tests, and the number of examined serological tests 211 over time for the general population, for the general population aged 33-53 and the population that 212 includes PLP and PWUD, respectively. As observed, the number of tests (both PCR and serological) 213 increased over time. Similarly, the number of prescribed DAA has increased over time.

214

Figures 1, 2 and 3 show the results obtained in the ARIMA model, in the general population, in the sub-population of individuals aged between 33 and 53 and in the sub-population of individuals that

217 are either PLP or PWUD, respectively. Tables reporting all the estimates are available in the Appendix 218 B. These three figures illustrate the results in the context of a counterfactual examination. In 219 particular, the actual values of the response variable (grey dots), the predicted values of the model 220 (blue line), the predicted values of the response variable obtained in the absence of the intervention 221 (orange line) and the predicted values of the response variable obtained in the presence of the 222 intervention but in the absence of the COVID pandemic (black line) are reported in these graphs. In 223 both figures, the orange line lies below the blue line indicating that the intervention had a positive 224 effect and improved HCV treatment coverage. Furthermore, as the black line lies above the blue line, 225 the impact of AIFA resolution was shrunk by the spread of the COVID pandemic. 226

- 227






Figure 1. ITS, ARIMA Results. Counterfactuals. General population



232

233 Figure 2. ITS, ARIMA Results. Counterfactuals. General population, people aged between 33 and 53.

234




239


240 Finally, Figure 4 presents a comparison of the estimated ARIMA coefficients (and 95% confidence

241 intervals) related to the effect of the intervention; Figure A4 in the Supplementary Material -

242 Appendix A shows the effect of the COVID pandemic for all identified sub-populations.



## 243



245

As can be observed, the effect of the intervention was positive and statistically significant for the general population and selected ages. However, the effect was non-significant for PLP and PWUD (figure 4). On the contrary, COVID-19 had a negative impact on all population groups, except for PLP for whom non-significant effect was observed (figure A4 Supplementary Material – Appendix A).

#### 253 DISCUSSION

254

Here we attempt to give an interpretation to the data obtained through an interrupted time series analysis used to assess the impact of the policies of the Region of Tuscany, Italy, promulgated to achieve the goals of HCV elimination as identified by the WHO.

258

259 Firstly, it is important to highlight the effect of relaxing the criteria for access to DAA treatment on 260 HCV diagnostic and therapeutic performance. Indeed, the 2017 AIFA resolution on extended access to 261 DAA made access to treatment universalistic, allowing all people living with HCV to start DAA therapy 262 regardless of the stage of liver fibrosis. This indicates that the Tuscany regional health authority raised 263 their awareness of the importance of preventing HCV, resulting in a progressive effort to enhance 264 screening and, consequently, the increase in initiated treatments with DAA. However, with the 265 passage of time, after the first wave of new treatment initiations, expanding access did not result in 266 sustained increases in the search for new cases through continuous and targeted screening, as Herink 267 and colleagues also pointed out in their study<sup>40</sup>. In fact, retesting of patients already linked to care,

prior to DAA treatment initiation may have contributed to the observed initial peak in screening.

269

A remark must be made about the high number of tests provided to women during the study period. Even before 2015, in Tuscany Region as well as in the national territory, a provision was in force - and still is - to test for HCV antibodies during the first trimester of pregnancy. This results in a high flow of tests provided to women of childbearing age, partly overlapping with the 1969-1989 birth cohort considered in the study. However, this screening effort does not correspond to a high number of HCV treatments prescribed to women, in line with other studies reporting a low prevalence of HCV among pregnant women<sup>41</sup>.

278 Parallel to the increase in access to diagnostic services, which led to an increased number of new 279 diagnoses, the number of patients initiated on treatment also saw a marked increase, particularly 280 between 2017 and 2018. This spike in the provision of DAA treatment in the first year after the AIFA 281 resolution can be explained by the fact that all patients already diagnosed and linked to care were 282 recalled to start treatment. The resolution had a positive and substantial effect on the increase in the 283 number of treatments provided because of the broadening of the inclusion criteria leading to universal 284 access. In addition the Regional Health Authority implemented the ministerial indications and 285 endorsed a regional HCV elimination plans, thereby favoring the linkage to care of people living with 286 HCV infection. As the work of Kondili and colleagues shows, the effect of the national resolution on 287 regional policies led Italy to be one of the twelve nations on course to meet the WHO's 2030 HCV 288 elimination targets, provided that 40 000 patients receive treatment year until 2030<sup>42</sup>. This trend was 289 also confirmed in other studies<sup>43</sup>.

290

291 As our results show, the effect of the intervention was positive and statistically significant in the 292 general population and the selected birth cohort. However, this effect becomes statistically non-293 significant in sub-populations consisting of PLP or PWUD. This finding could be explained with the fact 294 that both PLP and PWUD are well characterized for their heightened prevalence of HCV, and they may 295 have been targeted for HCV screening and treatment efforts before 2017. Although PWUD and PLP 296 may be engaged in screening programs via dedicated healthcare services, namely harm reduction 297 services or prison healthcare services, scarce evidence is available at local and national level as to the 298 extent of such interventions in recent years<sup>14</sup>. On the other hand, these results could be explained by 299 a scarce effort of public health authorities in targeting these specific populations before and after the 300 interventions, despite robust knowledge about drug use as a risk factor, as also demonstrated in 301 modeling studies<sup>44</sup>.

In order to tackle this and to promote the identification of undiagnosed cases, especially amongpopulation groups where virus transmission is most frequent, a region-wide screening campaign was

304 launched in 2023. Already since the end of 2022 in harm reduction services (SerDs) and prisons, an 305 intensified screening effort was launched. However, it is likely that the rate of acceptance and 306 initiation of treatment is lower in these settings, partly due to higher rate of treatment discontinuation 307 (e.g. post-release discontinuity of care) or suboptimal compliance, and partly due to the challenges in 308 reaching PWUDs who are not linked to harm reduction services.

309

310 In the general population, the triennial HCV elimination action plan promoted by the Tuscany Regional 311 Health Authority promoted access to DAA and increased the coverage of HCV treatment, as 312 demonstrated previously. This effect would have been even more pronounced if the COVID pandemic 313 had not affected the progress starting from March 2020. The COVID pandemic had a negative and 314 significant effect on the general population and on all examined sub-populations, resulting in a 315 reduced number of HCV treatment initiations . This evidence has been brought to light by a number 316 of other studies<sup>45-46</sup>. In particular, the work of Binka and colleagues<sup>47</sup>, through an interrupted time 317 series analysis, shows how public health measures related to COVID-19 had a negative effect on HCV 318 screening and diagnosis performance, reducing the number of HCV diagnoses in Canada. In parallel 319 and as a consequence of this, the number of treatments delivered also declined: global trends in DAA 320 utilisation have been explored extensively in a number of studies, which concluded on a negative 321 impact of the COVID-19 pandemic<sup>48</sup>. Konstantelos and colleagues have also shed light on the same 322 phenomenon in Ontario, Canada, obtaining results overlapping with those emerging from our work in 323 a high-income country with universalist health policies similar to Italy<sup>49</sup>. Because of the COVID-19 324 pandemic, as well as of other intervening factors, Tuscany Regional health authority failed to meet the 325 targets for treatment set in the 2018 regional action plan, in terms both of new treatments initiated 326 and new diagnosis.

327

328 Our research has some limitations. First of all, information on tests carried out by private providers 329 (such as non-governmental organizations) is not included in administrative health records used to

330 determine outpatient services and pharmaceutical services. Additionally, information on the 331 outcomes of laboratory tests and treatments could not be retrieved. We were unable to evaluate the 332 development of the HCV continuum of care because the laboratory test results of the patients were 333 unavailable. Yousafzai et al.<sup>50</sup> documented the HCV care cascade following the introduction of DAAs 334 in Australia in a recent study utilizing the same methodological technique by accessing HCV test results 335 through data linkage. Second, we gathered data on treatment prescriptions; however, since data on 336 patients' actual drug use was not available, we used prescriptions as a stand-in for DAA uptake, even 337 if we do not have information about the treatments' outcomes.

338

In order to, link data, we identified PWUD using exemption numbers. Though not particularly for intravenous drugs, the same code is linked to all substance use disorders, which likely causes an overestimation of PWUD in our study. However, acquiring an exemption code from the SSR requires linkage to care (such as HR services), which could result in an underestimate of the real PWUD population living in Tuscany throughout the study period.

344

Additionally, testing services given prior to 2015 were not considered because our analysis began with
the introduction of DAAs in that year. This might have caused the proportion of the Tuscan population
who had undergone HCV screening at least once to be underestimated.

348

## 349 CONCLUSIONS

The results of this study indicate a significant upsurge in activities associated with the screening of Hepatitis C Virus (HCV) in Tuscany between 2015 and 2022. Furthermore, it is evident that the triennial action plan implemented by the regional authorities following the 2017 AIFA resolution has substantially enlarged the treatment coverage of HCV in the general population and that the effect of the policy would have been even stronger if the COVID pandemic had not affected service provision since March 2020. In the sub-population of PLPs and PWUDs the effect of the intervention was not statistically significant, suggesting that treatment coverage remained substantially stable after the implementation of the policies. To conclude, the strategic policy implemented by the Tuscany Regional Health Authority following the AIFA resolution to enhance DAAs coverage has proven to be remarkably effective in the general population, while additional efforts may be needed to target equally effectively population sub-groups such as PLPs and PWUDs. Through a targeted approach, the region has succeeded in expanding access to DAA prescriptions, demonstrating a clear commitment to combating Hepatitis C.

363 The findings presented in this contribution serve as compelling evidence, urging other national and 364 subnational authorities to enhance HCV and streamline access to DAA prescriptions. In the years 365 immediately following the AIFA resolution, the regional plan of the Tuscany Region Health Authority 366 had an important effect in increasing the distribution of the treatment. However, it has not been as 367 effective in actively proposing screening for population groups at high risk of transmission, nor for the 368 general population. This is the context of the national screening program, to which Tuscany Region 369 has adhered, that will start in full force and effect in mid-2023. The role of the screening campaign is 370 crucial for several compelling reasons. First, timely screening enables the early detection of HCV 371 infections, facilitating swift intervention and treatment initiation. Identifying cases in the early stages 372 is critical to prevent disease progression and reduce the risk of severe complications. Second, promptly 373 detecting individuals with HCV curbs the potential for further transmission within communities. Lastly, 374 from a public health perspective, widespread screening aids in comprehending the virus's prevalence 375 in different communities, guiding targeted interventions and resource allocation for effective disease 376 management.

377

In addition to the screening campaign, it is also crucial to facilitate access to DAA prescriptions, to enhance treatment accessibility. Simplifying the procedures for healthcare providers to prescribe these antivirals for free ensures that affected individuals, regardless of their socio-economic status or geographic location, can readily access and benefit from modern, effective treatments. From a public

382	health perspective, early detection and treatment of HCV can lead to substantial healthcare cost
383	savings in the long run. Indeed, by preventing the progression of the disease to advanced stages,
384	authorities can reduce the economic burden associated with treating severe complications and
385	improve the efficiency of the whole healthcare system.
386	
387	From a broader perspective, increased screening and improved access to DAA prescriptions align with
388	the worldwide efforts to eliminate HCV as a public health threat. National and subnational authorities
389	play a pivotal role in contributing to international goals by implementing effective screening programs
390	and ensuring that appropriate treatments are readily available. In conclusion, findings of this study
391	provide evidence to support policies at national and subnational levels to booster HCV screening and
392	simplify access to DAA prescriptions. This not only enhances individual health outcomes but also holds
393	broader implications for public health, disease prevention, and global initiatives to eliminate HCV.
394	
395	
396	
397	
398	
399	
400	
401	
402	
403	
404	
405	
406	

407

## 408 Acknowledgments

409 This study was supported by the regional administration - Direzione Sanità, Welfare e Coesione sociale 410 - of Tuscany (Italy). The authors would like to thank the management and healthcare laboratory of 411 the Sant'Anna School of Advances Studies researchers in the person of Professor Milena Vainieri for 412 the chance to use data from Administrative Healthcare Records. More detailed data regarding the 413 effectiveness of the screening campaign will be available in the future to update this work. 414 415 416 **References:** 417 418 McHutchinson JG. Understanding Hepatitis C. The American Journal of Managed Care. 1. 419 2004;10(2). 420 2. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus 421 and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide q. 422 doi:10.1016/j.jhep.2006.05.013 423 3. Cui F, Blach S, Manzengo Mingiedi C, Gonzalez MA, Sabry Alaama A, Mozalevskis A, Séguy N, 424 Rewari BB, Chan PL, Le LV, Doherty M, Luhmann N, Easterbrook P, Dirac M, de Martel C, 425 Nayagam S, Hallett TB, Vickerman P, Razavi H, Lesi O, Low-Beer D. Global reporting of progress 426 towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023 Feb 427 7:S2468-1253(22)00386-7. doi: 10.1016/S2468-1253(22)00386-7. Epub ahead of print. PMID: 428 36764320. 429 4. Hofstraat SHI, Falla AM, Duffell EF, et al. Current prevalence of chronic hepatitis B and C virus 430 infection in the general population, blood donors and pregnant women in the EU/EEA: A 431 systematic review. Epidemiology and Infection. 2017;145(14):2873-2885. 432 doi:10.1017/S0950268817001947 433 5. Mason LM, Duffell E, Veldhuijzen IK, Petriti U, Bunge EM, Tavoschi L. Hepatitis B and C 434 prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a 435 Eurosurveillance. systematic review. 2019;24(30). doi:10.2807/1560-436 7917.ES.2019.24.30.1800614 437 6. Stasi C, Silvestri C, Voller F. Update on Hepatitis C Epidemiology: Unaware and Untreated 438 Infected Population Could Be the Key to Elimination. SN Compr Clin Med. 2020;2(12):2808-439 2815. doi: 10.1007/s42399-020-00588-3. Epub 2020 Oct 18. PMID: 33103061; PMCID: 440 PMC7568689. 441 7. Andriulli A, Stroffolini T, Mariano A, et al. Declining prevalence and increasing awareness of 442 HCV infection in Italy: A population-based survey in five metropolitan areas. European Journal 443 of Internal Medicine. 2018;53:79-84. doi:10.1016/j.ejim.2018.02.015 444 8. Mele A, Tosti ME, Spada E, Mariano A, Bianco E; SEIEVA Collaborative Group. Epidemiology of 445 Acute Viral Hepatitis: Twenty Years of Surveillance through SEIEVA in Italy and a Review of the 446 Literature. Rome: Istituto Superiore di Sanità (Rapporti Istisan 06/12); 2012. 447 9. Marascio N, Liberto MC, Barreca GS, et al. Update on epidemiology of HCV in Italy: focus 448 on the Calabria Region. BMC Infect Dis. 2014;14(Suppl 5):S2.

10. Torre GL, Gualano MR, Semyonov L, Nicolotti N, Ricciardi W, Boccia A. Hepatitis C virus
infection trends in Italy, 1996–2006. Hepat Mon. 2011;11:895–900.

- 451 11. Mennini FS, Marcellusi A, Andreoni M, Gasbarrini A, Salomone S, Craxì A. Health policy 452 model: long-term predictive results associated with the management of hepatitis C virus-453 induced diseases in Italy. Clin Outcomes Res. 2014;6:303-310.
- 454 12. Kondili LA, Andreoni M, Aghemo A, Mastroianni CM, Merolla R, Gallinaro V, Craxì A. Prevalence of hepatitis C virus estimates of undiagnosed individuals in different Italian 455 456 regions: a mathematical modelling approach by route of transmission and fibrosis progression 457 with results up to January 2021. New Microbiol. 2022 Dec;45(4):249-259. Epub 2022 May 25. 458 PMID: 36066213.
- 459 13. Andriulli A, Stroffolini T, Mariano A, Valvano MR, Grattagliano I, Ippolito AM, Grossi A, 460 Brancaccio G, Coco C, Russello M, Smedile A, Petrini E, Martini S, Gaeta GB, Rizzetto M. 461 Declining prevalence and increasing awareness of HCV infection in Italy: A population-based 462 survey in five metropolitan areas. Eur J Intern Med. 2018 Jul;53:79-84. doi: 463 10.1016/j.ejim.2018.02.015. Epub 2018 Feb 21. PMID: 29475770.
- 464 14. Silvestri C, Bartolacci S, Pepe P, Monnini M, Voller F, Cipriani F, Stasi C. Attempt to calculate 465 the prevalence and features of chronic hepatitis C infection in Tuscany using administrative 466 data. World J Gastroenterol. 2016 Nov 28;22(44):9829-9835. doi: 10.3748/wjg.v22.i44.9829. 467 PMID: 27956807; PMCID: PMC5124988.
- 468 15. Stasi C, Silvestri C, Pepe P, et al. Epidemiologia Dell'infezione Cronica Da HCV in Toscana.; 469 2017.
- 470 16. World Health Organization. Global Health Sector Strategy Towards Ending Viral Hepatitis. 471 Published online 2016. doi:https://doi.org/WHO/HIV/2016.06
- 472 17. World Health Organization Regional Office for Europe. Action Plan for the Health Sector 473 Response to Viral Hepatitis in the WHO European Region.; 2017. Accessed April 21, 2022. 474 http://www.euro.who.int/ data/assets/pdf file/0017/318320/European-action-plan-HSviralhepatitis. pdf?ua=1 475
- 476 18. Italian Ministry of Health. National Plan for the Prevention of Viral Hepatitis B and C.; 2015. 477 Accessed April 21, 2022. 478
  - https://www.salute.gov.it/imgs/C 17 pubblicazioni 2437 allegato.pdf
- 479 19. Mennini FS, Marcellusi A, Andreoni M, Gasbarrini A, Salomone S, Craxì A. Health policy 480 model: long-term predictive results associated with the management of hepatitis C virus-481 induced diseases in Italy. Clin Outcomes Res. 2014;6:303-310.
- 482 20. Kondili LA, Andreoni M, Aghemo A, Mastroianni CM, Merolla R, Gallinaro V, Craxì A. 483 Prevalence of hepatitis C virus estimates of undiagnosed individuals in different Italian 484 regions: a mathematical modelling approach by route of transmission and fibrosis progression 485 with results up to January 2021. New Microbiol. 2022 Dec;45(4):249-259. Epub 2022 May 25. 486 PMID: 36066213.
- 487 21. Italian Medicine Agency. Redefinition of Treatment Criteria for Chronic HCV Therapy 488 (Determina n. 500/2017).; 2017. Accessed April 2022. 21, 489 https://www.aifa.gov.it/sites/default/files/Determina n. 500-2017 Epatite-C.pdf
- 490 22. Giunta Regionale Regione Toscana, Estratto del Verbale della Seduta del 09.04.2018. Oggetto: 491 Progetto per la realizzazione di un programma per il controllo dell'epatite cronica C in Toscana 492 (DGR397/2018) [Regional Council Tuscany Region, Abstract of the Minutes of the Meeting of 493 09.04.2018. Subject: Project for the implementation of a program for the control of chronic 494 hepatitis С in Tuscany (DGR397/2018)]. Available from:

495	https://www.regione.toscana.it/bancadati/atti/Contenuto.xml?id=5177892&nomeFile=Deli
496	bera_n.397_del_09-04-2018 accessed July 18, 2022.
497	23. Giunta Regionale Regione Toscana. DGRT 1538/2022 "Avvio di un programma di screening
498	gratuito per prevenire, eliminare ed eradicare il virus dell'epatite C, in attuazione dell'art. 25-
499	sexies del D.L.n. 162/2019. Approvazione del progetto". [Regional Council Tuscany Region.
500	DGRT 1538/2022 "Launch of a free screening programme to prevent, eliminate and eradicate
501	the hepatitis C virus, in implementation of art. 25-sexies of D.L.n. 162/2019. Approval of the
502	project"], 2022.
503	24. Ferré F, De Belvis AG, Valerio L, Longhi S, Lazzari A, Fattore G, et al. Italy: healthsystem review.
504	Health Systems in Transition 2014;16(4):1–168.
505	25. James Lopez Bernal, Steven Cummins, and Antonio Gasparrini. Interrupted time series
506	regression for the evaluation of public health interventions: a tutorial. International journal of
507	epidemiology, 46(1):348–355, 2017.
508	26. David McDowall, Richard McCleary, and Bradley J Bartos. Interrupted time series analysis.
509	Oxford University Press, 2019.
510	27. Anita K Wagner, Stephen B Soumerai, Fang Zhang, and Dennis Ross-Degnan. Segmented
511	regression analysis of interrupted time series studies in medication use research. Journal of
512	clinical pharmacy and therapeutics, 27(4):299–309, 2002.
513	28. Robert B Penfold and Fang Zhang. Use of interrupted time series analysis in evaluating health
514	care quality improvements. Academic pediatrics, 13(6):S38–S44, 2013.
515	29. Carl Bonham, Edwin Fujii, Eric Im, and James Mak. The impact of the hotel room tax: an
516	interrupted time series approach. National Tax Journal, 45(4):433–441, 1992.
517	30. James A Lopez Bernal, Antonio Gasparrini, Carlos M Artundo, and Martin McKee. The effect
518	of the late 2000s financial crisis on suicides in spain: an interrupted time-series analysis. The
519	European Journal of Public Health, 23(5):732–736, 2013.
520	31. Barry S Rundquist and David E Griffith. An interrupted time-series test of the distributive
521	theory of military policy-making. Western Political Quarterly, 29(4):620–626, 1976.
522	32. William Alex Pridemore, Mitchell B Chamlin, and John K Cochran. An interrupted time-series
523	analysis of durkheim's social deregulation thesis: The case of the russian federation. Justice
524	Quarterly, 24(2):271–290, 2007.
525	33. Marie-Andrée Somers, Pei Zhu, Robin Jacob, and Howard Bloom. The validity and precision of
526	the comparative interrupted time series design and the difference-in-difference design in
527	educational evaluation. MDRC, 2013.
528	34. Kelly Hallberg, Ryan Williams, Andrew Swanlund, and Jared Eno. Short comparative
529	interrupted time series using aggregate school-level data in education research. Educational
530	Researcher, 47(5):295–306, 2018.
531	35. Paul Newbold. Arima model building and the time series analysis approach to forecasting.
532	Journal of forecasting, 2(1):23–35, 1983.
533	36. Adebiyi A Ariyo, Adewumi O Adewumi, and Charles K Ayo. Stock price prediction using the
534	arima model. In 2014 UKSim-AMSS 16th international conference on computer modelling and
535	simulation, pages 106–112. IEEE, 2014.
536	37. Steven Craig Hillmer and George C Tiao. An arima-model-based approach to seasonal
537	adjustment. Journal of the American Statistical Association, 77(377):63–70, 1982.
538	38. Dhamo Gjika, Eralda & Puka, Llukan. (2010). Using the R-package to forecast time series:
539	ARIMA models and Application.
	······································

- 540 39. Peterson, R. A., & Cavanaugh, J. E. (2019). Ordered quantile normalization: a semiparametric
   541 transformation built for the cross-validation era. Journal of applied statistics.
- 40. Megan C Herink, Jonah Geddes, Kim Vo, Atif Zaman, and Daniel M Hartung. Effect of relaxing
  hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an
  interrupted time series analysis. Journal of Managed Care & Specialty Pharmacy 2021 27:7,
  856-864
- 546 41. Pott H Junior, Theodoro M, de Almeida Vespoli J, Senise JF, Castelo A. Mother-to-child
  547 transmission of hepatitis C virus. Eur J Obstet Gynecol Reprod Biol. 2018 May;224:125-130.
  548 doi: 10.1016/j.ejogrb.2018.03.034. Epub 2018 Mar 20. PMID: 29597101.
- 549 42. Loreta A Kondili, Lucia Craxì, Felice Nava, Sergio Babudieri, Roberta D'Ambrosio, Andrea 550 Marcellusi, Francesco Saverio Mennini, Sabrina Valle, Pierluigi Russo, Pier Paolo Olimpieri, 551 Massimo Andreoni, Alessio Aghemo, From Prioritization to Universal Treatment: Successes 552 and Challenges of Hepatitis C Virus Elimination in Italy, The Journal of Infectious Diseases, 553 Volume 228, Issue Supplement 3, 15 September 2023, Pages S211-S220, 554 https://doi.org/10.1093/infdis/jiad038
- 55543. Gamkrelidze I, Pawlotsky J-M, Lazarus JV, et al. Progress towards hepatitis C virus elimination556in high-income countries: an updated analysis. Liver Int 2021; 41:456–63.
- 44. Blach, S.; Kondili, L.A.; Aghemo, A.; Cai, Z.; Dugan, E.; Estes, C.; Gamkrelidze, I.; Ma, S.;
  Pawlotsky, J.M.; Razavi-Shearer, D.; et al. Impact of COVID-19 on global HCV elimination
  efforts. J. Hepatol. 2021, 74, 31–36. [Google Scholar] [CrossRef] [PubMed]
  - 45. Trickey A, Fraser H, Lim AG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4(6):435-44. Crossref, Medline, Google Scholar
- 46. Wingrove C, Ferrier L, James C, Wang S. The impact of COVID-19 on hepatitis elimination.
  Lancet Gastroenterol Hepatol. 2020; 5(9): 792-794.
- 565 47. Binka M, Bartlett S, Velásquez García HA, Darvishian M, Jeong D, Adu P, Alvarez M, Wong S,
  566 Yu A, Samji H, Krajden M, Wong J, Janjua NZ. Impact of COVID-19-related public health
  567 measures on HCV testing in British Columbia, Canada: An interrupted time series analysis.
  568 Liver Int. 2021 Dec;41(12):2849-2856. doi: 10.1111/liv.15074. Epub 2021 Oct 13. PMID:
  569 34592046; PMCID: PMC8662267.
- 48. Shakeri, A.; Konstantelos, N.; Chu, C.; Antoniou, T.; Feld, J.; Suda, K.J.; Tadrous, M. Global
  Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time
  Series Analysis. Viruses 2021, 13, 1314. <u>https://doi.org/10.3390/v13071314</u>
- 49. Konstantelos, N.; Shakeri, A.; McCormack, D.; Feld, J.J.; Gomes, T.; Tadrous, M. Impact of
  COVID-19 on prescribing trends of direct-acting antivirals for the treatment of Hepatitis, C. in
  Ontario, Canada. Am. J. Gastroenterol. 2021. [Google Scholar] [CrossRef]
- 576 50. Yousafzai MT, Alavi M, Valerio H, Hajarizadeh B, Grebely J, Dore GJ. Hepatitis C care cascade
  before and during the direct-acting antiviral eras in New South Wales, Australia: A populationbased linkage study. J Viral Hepat. 2023 Mar;30(3):250-261. doi: 10.1111/jvh.13791. Epub
  2023 Jan 11. PMID: 36537024.

580

560

561

562

582